Correção da Resistência à Insulina com o Uso do Mio-inositol na Síndrome do Ovário Policístico

Anne Gabriele Marques; Anna Clara Consalter Richter; Ana Júlia Silva Pelegrina; Isadora de Araújo Bosco Pacheco; Luciano Henrique Pinto; Daniela Delwing-de Lima; Gastão Schwarz Junior

doi:10.36489/saudecoletiva.2025v15i95p15552-15565

Authors

Anne Gabriele Marques Acadêmica do 10° semestre de Medicina; na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0003-1617-0998
Anna Clara Consalter Richter Acadêmica do 10° semestre de Medicina; na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0002-2219-4008
Ana Júlia Silva Pelegrina Acadêmica do 10° semestre de Medicina; na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0002-6957-186X
Isadora de Araújo Bosco Pacheco Acadêmica do 10° semestre de Medicina; na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0003-3763-4528
Luciano Henrique Pinto Docente do Departamento de Medicina na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0003-0250-7502
Daniela Delwing-de Lima Docente do Departamento de Medicina e do Programa de Pós-Graduação em Saúde e Meio Ambiente na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. Programa de Pós-Graduação em Saúde e Meio Ambiente - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0001-5335-5102
Gastão Schwarz Junior Docente do Departamento de Medicina e do Programa de Pós-Graduação em Saúde e Meio Ambiente na Universidade da Região de Joinville - UNIVILLE. Departamento de Medicina - Universidade da Região de Joinville - UNIVILLE - Joinville SC. https://orcid.org/0000-0002-7256-8530

DOI:

https://doi.org/10.36489/saudecoletiva.2025v15i95p15552-15565

Keywords:

Polycystic Ovary Syndrome, Metformin, Inositol 1,4,5-Trisphosphate

Abstract

Objective: To present the main endocrine and metabolic aspects of Polycystic Ovary Syndrome, as well as to discuss therapeutic alternatives to improve clinical outcomes and patients' quality of life. Method: Literature review on traditional and emerging therapeutic approaches, including new options such as Myo-inositol, considering the pathophysiology and consequences of Polycystic Ovary Syndrome. Result: Polycystic Ovary Syndrome is associated with type 2 diabetes and cardiovascular disease. Metformin has limited effectiveness in reducing weight and cardiovascular risk, while alternative therapies, such as incretin mimetics and Myo-inositol, have shown benefits in improving hormonal levels, follicular development, and oocyte maturation. Conclusion: The treatment of Polycystic Ovary Syndrome should involve expanded strategies addressing both metabolic and reproductive aspects. New therapies have shown promise in improving clinical outcomes, reinforcing the need for a more comprehensive approach to managing the condition.

DESCRIPTORS: Polycystic Ovary Syndrome; Metformin; Inositol 1,4,5-Trisphosphate.

References

Kamenov Z, Gateva A. Inositols in PCOS. Molecules. 2020;25(23):5566. doi:10.3390/molecules25235566.

Wawrzkiewicz-Jałowiecka A, Kowalczyk K, Cieślik M, Stachoń A, Ciosek J, Jabłonka-Salach K, et al. In search of new therapeutics Molecular aspects of the PCOS pathophysiology: genetics, hormones, metabolism and beyond. Int J Mol Sci. 2020;21(19):7054. doi:10.3390/ijms21197054.

Abdalla MA, Deshmukh H, Atkin SL, Sathyapalan T. A review of therapeutic options for managing the metabolic aspects of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020;11:2042018820938305. doi:10.1177/2042018820938305.

Mahalingaiah S, Diamanti-Kandarakis E. Targets to treat metabolic syndrome in polycystic ovary syndrome. Expert Opin Ther Targets. 2015;19(11):1561–74. doi:10.1517/14728222.2015.1101067.

Sortino MA, Salomone S, Carruba MO, Drago F. Polycystic ovary syndrome: Insights into the therapeutic approach with inositols. Front Pharmacol. 2017;8:341. doi:10.3389/fphar.2017.00341.

Pani A, Gironi A, Pandolfi A, Migliaccio S, Bertoletti G, Sorrentino F, et al. From prediabetes to type 2 diabetes mellitus in women with polycystic ovary syndrome: Lifestyle and pharmacological management. Int J Endocrinol. 2020;2020:6276187. doi:10.1155/2020/6276187.

Romualdi D, Costantini B, Lanzone A, Guido M. What is new in the landscape of insulin-sensitizing agents for polycystic ovary syndrome treatment. Ther Adv Reprod Health. 2020;14:2633494120908709. doi:10.1177/2633494120908709.

Cunha A, Póvoa AM. Infertility management in women with polycystic ovary syndrome: A review. Porto Biomed J. 2021;6(1):e116. doi:10.1097/j.pbj.0000000000000116.

Davinelli S, Nicolosi D, Di Cesare C, Scapagnini G, Di Marco R. Targeting metabolic consequences of insulin resistance in polycystic ovary syndrome by d-chiro-inositol and emerging nutraceuticals: A focused review. J Clin Med. 2020;9(4):987. doi:10.3390/jcm9040987.

Arie WM, Neto FCM, Maciel C. Síndrome do ovário policístico e metformina: revisão baseada em evidências. Femina. 2009;37(11). Available from: http://files.bvs.br/upload/S/0100-7254/2009/v37n11/a002.pdf.

Unfer V, Facchinetti F, Orrù B, Giordani B, Nestler JE. Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocr Connect. 2017;6(8):647–58. doi:10.1530/EC-17-0243.

Vale VAL, Queiroz JH, Reis TM, Zaidan MB, Almeida VV. O uso de metformina no tratamento da síndrome dos ovários policísticos. Braz J Health Rev. 2021;4(2):4426–36. doi:10.34119/bjhrv4n2-036.

Rocha AL, Oliveira FR, Azevedo RC, Lima RV, Júnior ZG. Recent advances in the understanding and management of polycystic ovary syndrome. F1000Res. 2019;8:565. doi:10.12688/f1000research.15098.1.

Le Donne M, Alibrandi A, Lo Presti VD, Giordano D, D’Anna R. Effects of three treatment modalities (diet, myoinositol or myoinositol associated with d-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. Eur Rev Med Pharmacol Sci. 2019;23(5):2293–301. doi:10.26355/eurrev_201903_17278.

Facchinetti F, Unfer V, Dewailly D, Diamanti-Kandarakis E, Jensen JT, La Marca A, et al. Experts’ opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: A further help for human reproduction and beyond. Expert Opin Drug Metab Toxicol. 2020;16(3):255–74. doi:10.1080/17425255.2020.1737675.

Andrade MVC. O uso de mio-inositol em mulheres com SOP: uma revisão integrativa. Rev Bras Obesidade Nutr Emagrecimento. 2022;16(99):120-130. doi:10.5327/Z1981-469020221699.

Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang and Dale's pharmacology. 7th ed. London: Elsevier/Churchill Livingstone; 2011.

Tambo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Torbergsen T. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018;97(10):1162-71. doi:10.1111/aogs.13395.